Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article only introduces drugs related to healthcare and is not a recommendation of treatment plans (if involved); it does not constitute any investment advice.
Recently, BRL Medicine announced that the research results of its "Targeted CD19 Non-viral PD1 Site-specific Integration CAR-T Cell Injection" (Pipeline Code: BRL-201) will be presented for the first time in2024 ASCO ConferencePublic debut.BRL-201 was independently developed by BRL Medicine.The non-viral site-specific integration CAR-T platform (Quikin CART® platform) developed CAR-T product, alsoWorld's First Targeted CD19 Non-Viral PD1-CAR-T Product，Indications: Relapsed/Refractory B-cellNon-Hodgkin's Lymphoma（R/R B-NHL）。Non-viral targeted integration CAR-T platform (Quikin CART) uses CRISPR gene editing technology to achieve gene knockout and targeted stable integration of CAR components.Quikin CAR-T has the advantages of simple process, short preparation time, and high product uniformity, and also avoids the tumorigenic risk caused by random integration.The PD1-CD19-CART product developed by this platform contains the PD1 gene.Dual Advantages of Knockout and CAR Homogeneous Stable Expression；This platform can also be used for the preparation of multiple immune checkpoint knockout-enhanced CAR-T cells, rapid production of universal CAR-T cells, and development of dynamically regulated safe CAR-T products, providing strong technical support for future CAR-T cell modifications.
▲ Quikin CART® Platform MechanismTo be announced at this year's ASCO is BRL-201 fromIITThe latest clinical data in the study. The results show that a total of 21 patients received BRL-201 treatment, with an objective response rate (ORR) as high as100%, Complete Response Rate (CR) reached85.7%。While achieving significant efficacy,Not caused in any patientCytokine release syndrome or neurotoxicity above grade 2. To date, the world's first patient to receive BRL-201 treatment from BRL Medicine has been cancer-free for over three years. This study demonstrates the excellent clinical safety and efficacy of the BRL-201 product, which can be said to beSo far, globallyHigh Remission Rate and Low Toxicity in CAR-T Cell Therapy for Refractory and Relapsed LymphomaBest Clinical Outcomes。Moreover, the research findings of this product were published on August 31, 2022, in a top international academic journal.NaturePublished on.01 Low cost, can benefit more patients
BRL-201 utilizes the 2020 Nobel Prize-winning CRISPR/Cas9 gene editing technology to precisely edit the PD1 site in T lymphocytes and insert a CAR molecule targeting CD19 in tumor cells, without the use of viral vectors. The non-viral production process can significantly reduce the high costs associated with using viral vectors and simplify the complex production process.02 Fast preparation, suitable for patients with rapid progressionPatient
BRL-201 is produced using a non-viral method, with a simple process that requires only one step to simultaneously achieve sustained CAR expression and regulation of endogenous genes in T cells. This significantly shortens the entire CAR-T production time, with a minimum of 3 days required for completion, greatly enhancing production capacity and enabling timely treatment for patients with rapidly progressing tumors.03 Safer, ensuring product uniformity
Non-viral targeted integration allows each CAR sequence to be precisely inserted into a specific site of the genome, avoiding the risk of tumorigenicity caused by random insertion, and maximizing the safety and efficacy of CAR-T products.04 MoreEffective, Break the Shackles of Recurrence and Refractoriness
Clinical Research Results of BRL-201 Demonstrate Outstanding Clinical Efficacy, Representing the Best Clinical Outcomes with High Remission Rates and Low Toxicity in Global CAR-T Cell Therapy for Refractory and Relapsed Lymphoma to Date. The Objective Response Rate (ORR) Reached 100%, and the Complete Response Rate (CR) Achieved 85.7%. Patients Showed Significantly Greater Long-Term Benefits Compared to Existing Similar Viral CAR-T Products. As of January 10, 2024, the Median Progression-Free Survival (mPFS) Reached 19.5 Months. Single-Cell Sequencing Results Indicate a High Proportion of Memory T Cells in the BRL-201 Cell Product, Exhibiting Stronger Anti-Tumor Immune Function, and the Infused CAR-T Cells Possess Long-Term Persistence.Source of the article:BRL Medicine Laboratory
